MX2020004771A - Metodos de tratamiento y terapia de mantenimiento para el cancer de vejiga con gemcitabina. - Google Patents

Metodos de tratamiento y terapia de mantenimiento para el cancer de vejiga con gemcitabina.

Info

Publication number
MX2020004771A
MX2020004771A MX2020004771A MX2020004771A MX2020004771A MX 2020004771 A MX2020004771 A MX 2020004771A MX 2020004771 A MX2020004771 A MX 2020004771A MX 2020004771 A MX2020004771 A MX 2020004771A MX 2020004771 A MX2020004771 A MX 2020004771A
Authority
MX
Mexico
Prior art keywords
methods
gemcitabine
treatment
maintenance therapy
bladder cancer
Prior art date
Application number
MX2020004771A
Other languages
English (en)
Inventor
Christopher Cutie
Dennis Giesing
Original Assignee
Taris Biomedical Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taris Biomedical Llc filed Critical Taris Biomedical Llc
Publication of MX2020004771A publication Critical patent/MX2020004771A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proporcionan metodos para tratar carcinomas uroteliales del tracto inferior que comprenden administrar gemcitabina continuamente y localmente a la vejiga de un individuo en una terapia de induccion y/o terapia de mantenimiento.
MX2020004771A 2017-11-08 2018-11-07 Metodos de tratamiento y terapia de mantenimiento para el cancer de vejiga con gemcitabina. MX2020004771A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762583394P 2017-11-08 2017-11-08
PCT/US2018/059698 WO2019094517A1 (en) 2017-11-08 2018-11-07 Methods of treatment and maintenance therapy for bladder cancer using gemcitabine

Publications (1)

Publication Number Publication Date
MX2020004771A true MX2020004771A (es) 2020-10-19

Family

ID=66439297

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020004771A MX2020004771A (es) 2017-11-08 2018-11-07 Metodos de tratamiento y terapia de mantenimiento para el cancer de vejiga con gemcitabina.
MX2023007680A MX2023007680A (es) 2017-11-08 2020-07-13 Metodos de tratamiento y terapia de mantenimiento para el cancer de vejiga con gemcitabina.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023007680A MX2023007680A (es) 2017-11-08 2020-07-13 Metodos de tratamiento y terapia de mantenimiento para el cancer de vejiga con gemcitabina.

Country Status (18)

Country Link
US (3) US10792297B2 (es)
EP (1) EP3706763A4 (es)
JP (2) JP2021502347A (es)
KR (1) KR20200085822A (es)
CN (1) CN111787926A (es)
AU (1) AU2018366106A1 (es)
BR (1) BR112020008700A2 (es)
CA (1) CA3081839A1 (es)
DO (1) DOP2023000155A (es)
EA (1) EA202091143A1 (es)
IL (2) IL302714A (es)
JO (1) JOP20200124A1 (es)
MA (1) MA50581A (es)
MX (2) MX2020004771A (es)
PE (1) PE20210041A1 (es)
PH (1) PH12020550587A1 (es)
SG (1) SG11202003950WA (es)
WO (1) WO2019094517A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10857173B2 (en) 2017-07-25 2020-12-08 Taris Biomedical Llc Methods of treating tumor metastasis
WO2024092159A1 (en) * 2022-10-28 2024-05-02 Taris Biomedical Llc Methods of treating bladder cancer with gemcitabine

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG177362A1 (en) 2009-06-26 2012-02-28 Taris Biomedical Inc Solid drug tablets for implantable drug delivery devices
US9017312B2 (en) 2009-09-10 2015-04-28 Taris Biomedical Llc Implantable device for controlled drug delivery
HUE053888T2 (hu) 2009-12-17 2021-07-28 Taris Biomedical Llc Intravezikálisan tolerálható beültethetõ eszköz
NZ708506A (en) 2010-06-02 2016-08-26 Abraxis Bioscience Llc Methods of treating bladder cancer
SI2600800T1 (sl) 2010-08-05 2021-03-31 Taris Biomedical Llc Naprava za dovajanje zdravila preko sečevodnega stenta in komplet
KR20140048086A (ko) 2011-02-04 2014-04-23 타리스 바이오메디컬 인코포레이티드 저 용해성 약물의 제어 방출을 위한 이식가능한 디바이스
CA2868431A1 (en) 2012-03-29 2013-10-03 Altor Bioscience Corporation Methods for treating neoplasia
MX367070B (es) 2012-08-31 2019-08-05 Taris Biomedical Llc Sistemas de administracion de farmaco y metodos para el tratamiento de la prostata.
MX365688B (es) 2012-08-31 2019-06-11 Taris Biomedical Llc Sistemas de administracion de farmaco y metodos para el tratamiento del cancer de vejiga que comprenden oxaliplatino.
WO2014138214A1 (en) 2013-03-05 2014-09-12 Taris Biomedical, Inc. Drug delivery devices and methods for controlled drug release through device orifice
NZ711416A (en) 2013-03-15 2018-02-23 Taris Biomedical Llc Drug delivery devices and methods for drug delivery
MX2015012367A (es) 2013-03-15 2016-05-31 Taris Biomedical Llc Dispositivos de suministro de farmacos con un componente permeable al farmaco y metodos.
DE102013103986A1 (de) 2013-04-19 2014-10-23 B. Braun Avitum Ag Rezirkulationsvorrichtung eines extrakorporalen Blutbehandlungsgeräts
KR102385603B1 (ko) 2013-08-19 2022-04-11 타리스 바이오메디컬 엘엘씨 다중 유닛 약물 전달 장치 및 방법
PL3113782T3 (pl) * 2014-03-06 2023-01-23 Taris Biomedical Llc Układy podawania leku i sposoby leczenia raka pęcherza moczowego gemcytabiną
WO2015200752A1 (en) 2014-06-26 2015-12-30 Taris Biomedical Llc Intravesical drug delivery devices and methods including elastic polymer-drug matrix systems
US10894150B2 (en) 2015-04-23 2021-01-19 Taris Biomedical Llc Drug delivery devices with drug-permeable component and methods
JP2019514970A (ja) 2016-05-06 2019-06-06 タリス バイオメディカル エルエルシー 下部尿路上皮がんを処置する方法
US10857173B2 (en) 2017-07-25 2020-12-08 Taris Biomedical Llc Methods of treating tumor metastasis
US11464734B2 (en) 2018-08-01 2022-10-11 Taris Biomedical Llc Methods of treating overactive bladder using trospium

Also Published As

Publication number Publication date
US20210085705A1 (en) 2021-03-25
US20230321129A1 (en) 2023-10-12
MA50581A (fr) 2020-09-16
EP3706763A4 (en) 2021-08-11
IL302714A (en) 2023-07-01
IL274343B2 (en) 2023-10-01
IL274343A (en) 2020-06-30
BR112020008700A2 (pt) 2020-10-27
PE20210041A1 (es) 2021-01-08
US10792297B2 (en) 2020-10-06
JP2024009888A (ja) 2024-01-23
MX2023007680A (es) 2023-07-07
JP2021502347A (ja) 2021-01-28
DOP2023000155A (es) 2023-12-29
PH12020550587A1 (en) 2021-04-26
EP3706763A1 (en) 2020-09-16
WO2019094517A1 (en) 2019-05-16
US20190175637A1 (en) 2019-06-13
CA3081839A1 (en) 2019-05-16
JOP20200124A1 (ar) 2020-05-20
AU2018366106A1 (en) 2020-05-14
KR20200085822A (ko) 2020-07-15
IL274343B1 (en) 2023-06-01
CN111787926A (zh) 2020-10-16
EA202091143A1 (ru) 2020-07-30
SG11202003950WA (en) 2020-05-28

Similar Documents

Publication Publication Date Title
CL2018001152A1 (es) Composiciones y métodos para el tratamiento del cáncer
CO2017007662A2 (es) Terapias de combinación para el tratamiento de cánceres
CL2018003123A1 (es) Terapia de combinación para el tratamiento del cáncer
DOP2023000155A (es) Tratamiento y terapia de mantenimiento para el cáncer de vejiga con gemcitabina
BR112018013731A2 (pt) combinações anti-egfr para o tratamento de tumores
PE20180673A1 (es) Tratamiento contra el cancer por manipulacion de la microflora comensal
EA201790737A1 (ru) Комбинированная терапия
UY36307A (es) Terapias combinadas para el tratamiento del cáncer
MX2022008868A (es) Tratamiento del cancer con tg02.
BR112017018964A2 (pt) uso de plinabulin e métodos para tratar tumor cerebral
BR112017016772A2 (pt) bactérias probióticas recombinantes para uso no tratamento de uma disfunção inflamatória da pele e método para tratá-la
MX2021000847A (es) Procedimientos para el tratamiento del cancer con el inhibidor de pi3k, gdc 0077.
CL2019000846A1 (es) Proteína terapéutica.
CO2020001107A2 (es) Moduladores terapéuticos del modo inverso de la atp sintasa
JO3541B1 (ar) علاجات طبية قائمة على اناموريلين
CL2023003090A1 (es) Combinaciones de composiciones terapéuticas y usos para tratar cánceres
MX2019002479A (es) Nnif y péptidos relacionados con nnif y métodos relacionados.
MX2019001337A (es) Métodos para tratar y prevenir efectos secundarios por tratamiento de cáncer.
GT201400071A (es) Combinación terapéutica para el tratamiento de cáncer
CY1125266T1 (el) To rad1901 για χρηση στη θεραπεια του καρκινου των ωοθηκων
IL275913A (en) Methods and combined treatment for cancer treatment
MX2021001081A (es) Terapia de combinacion para el tratamiento del cancer.
CR20140480A (es) Metodos para tratar el cancer usando inhibidor de pi3k e inhibidor de mek
DOP2014000258A (es) Tratamiento de la metástasis en el cerebro con una combinación de veliparib y una terapia con radiación en la totalidad del cerebro
EA201990411A1 (ru) Способы лечения рака предстательной железы